Astellas Pharma vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Astellas Pharma Inc. (4503.JP)

Q3 202615 Jul – 2 Sep 2026

▲3▼1

Astellas: strong Q1 and new bladder-cancer approval, but Trump pricing deal adds pressure

FDA approves PADCEV plus Keytruda for muscle-invasive bladder cancer The FDA approved Astellas and Pfizer's PADCEV combined with Keytruda for muscle-invasive bladder cancer, the first platinum-free regimen for this disease. This widens the patient group that can use the treatment, which should lift future sales of this key Astellas drug.
A new US approval directly expands the market for an Astellas product, a core driver of future revenue.
Q1 profit surges and full-year guidance raised Astellas reported first-quarter profit of 141.81 billion yen, more than double last year, with revenue up sharply. It guided fiscal 2027 revenue to grow 3.8% to 2.22 trillion yen and profit to rise 2.9%. Strong results and upbeat guidance support the stock.
Earnings and guidance are the most direct fundamental driver of the share price.
Health Canada approves Keytruda plus enfortumab vedotin for bladder cancer Health Canada approved Merck's Keytruda with enfortumab vedotin, which Astellas co-developed, for muscle-invasive bladder cancer. This adds another country where the combination can be sold, supporting Astellas's share of revenue from the drug.
A new geographic approval broadens the commercial reach of an Astellas-partnered therapy.
Astellas joins Trump's Medicaid most-favored-nation pricing deals Astellas agreed to give Medicaid the lowest prices it charges anywhere and to help build US manufacturing in exchange for tariff relief. This limits future US pricing power and could pressure revenue, though tariff relief and goodwill are partial offsets.
The pricing agreement is a direct regulatory hit to Astellas's US drug pricing and a key new overhang.

August 202615 Jul – 2 Sep 2026

▲3▼1

Astellas: strong Q1 and new bladder-cancer approval, but Trump pricing deal adds pressure

FDA approves PADCEV plus Keytruda for muscle-invasive bladder cancer The FDA approved Astellas and Pfizer's PADCEV combined with Keytruda for muscle-invasive bladder cancer, the first platinum-free regimen for this disease. This widens the patient group that can use the treatment, which should lift future sales of this key Astellas drug.
A new US approval directly expands the market for an Astellas product, a core driver of future revenue.
Q1 profit surges and full-year guidance raised Astellas reported first-quarter profit of 141.81 billion yen, more than double last year, with revenue up sharply. It guided fiscal 2027 revenue to grow 3.8% to 2.22 trillion yen and profit to rise 2.9%. Strong results and upbeat guidance support the stock.
Earnings and guidance are the most direct fundamental driver of the share price.
Health Canada approves Keytruda plus enfortumab vedotin for bladder cancer Health Canada approved Merck's Keytruda with enfortumab vedotin, which Astellas co-developed, for muscle-invasive bladder cancer. This adds another country where the combination can be sold, supporting Astellas's share of revenue from the drug.
A new geographic approval broadens the commercial reach of an Astellas-partnered therapy.
Astellas joins Trump's Medicaid most-favored-nation pricing deals Astellas agreed to give Medicaid the lowest prices it charges anywhere and to help build US manufacturing in exchange for tariff relief. This limits future US pricing power and could pressure revenue, though tariff relief and goodwill are partial offsets.
The pricing agreement is a direct regulatory hit to Astellas's US drug pricing and a key new overhang.

Latest15 Jul – 2 Sep 2026

▲3▼1

Astellas: strong Q1 and new bladder-cancer approval, but Trump pricing deal adds pressure

FDA approves PADCEV plus Keytruda for muscle-invasive bladder cancer The FDA approved Astellas and Pfizer's PADCEV combined with Keytruda for muscle-invasive bladder cancer, the first platinum-free regimen for this disease. This widens the patient group that can use the treatment, which should lift future sales of this key Astellas drug.
A new US approval directly expands the market for an Astellas product, a core driver of future revenue.
Q1 profit surges and full-year guidance raised Astellas reported first-quarter profit of 141.81 billion yen, more than double last year, with revenue up sharply. It guided fiscal 2027 revenue to grow 3.8% to 2.22 trillion yen and profit to rise 2.9%. Strong results and upbeat guidance support the stock.
Earnings and guidance are the most direct fundamental driver of the share price.
Health Canada approves Keytruda plus enfortumab vedotin for bladder cancer Health Canada approved Merck's Keytruda with enfortumab vedotin, which Astellas co-developed, for muscle-invasive bladder cancer. This adds another country where the combination can be sold, supporting Astellas's share of revenue from the drug.
A new geographic approval broadens the commercial reach of an Astellas-partnered therapy.
Astellas joins Trump's Medicaid most-favored-nation pricing deals Astellas agreed to give Medicaid the lowest prices it charges anywhere and to help build US manufacturing in exchange for tariff relief. This limits future US pricing power and could pressure revenue, though tariff relief and goodwill are partial offsets.
The pricing agreement is a direct regulatory hit to Astellas's US drug pricing and a key new overhang.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

September 202627 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.

Latest27 Jul – 8 Oct 2026

▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.
Shows pipeline progress that can lift long-term growth expectations for the stock.
National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.
Directly increases expected product demand and market share, a core earnings driver.
Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.
Earnings growth and shareholder returns are the main fundamental supports for the share price.
Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.
These are the main counterweights that could hurt sentiment and valuation.